|
|
|
|
|
|
|
|
JAMA Oncology
Full content is available to subscribers
Subscribe/Learn More
Viewpoint
|
September 08, 2016
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3046
This
Viewpoint discusses the significance of investing billions of dollars
in genomic sequencing and the implications of finding a hereditary
mutation in patients with metastatic cancer using next-generation
sequencing.
An
announcement was made regarding the initiation of a “moonshot” approach
to the multifaceted cancer problems with the intent on reducing cancer
mortality in the United States by accelerating cancer research to
discover more therapies and focusing on finding new ways to prevent
cancer and detect it in an early stage before it spreads. President
Obama’s proposed fiscal year 2017 budget includes $1 billion for
eliminating cancer. This initiative has led to the belief that
concentrating on treatment is a limited approach to the overall
reduction of cancer mortality, considering the success of cancer
research in prevention.1
However, a powerful method for cancer prevention and survival has been
the discipline of hereditary cancer syndromes. In this article, we
discuss the significance of investing billions of dollars in genomic
sequencing and the implications of finding a hereditary mutation in
patients with metastatic cancer using next-generation sequencing (NGS).
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.